BioNexus Gene Lab Corp. Financing Interest Expense
BioNexus Gene Lab Corp. (BGLC) reported Financing Interest Expense of $4.05 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Interest Expense
us-gaap:FinancingInterestExpense · last filed 2026-08-14
- BioNexus Gene Lab Corp. financing interest expense for the quarter ending 2026-06-30 was $4.05K, a 16.89% decline year-over-year.
- BioNexus Gene Lab Corp. financing interest expense for the quarter ending 2026-03-31 was $3.08K, a 37.16% decline year-over-year.
- BioNexus Gene Lab Corp. financing interest expense for the quarter ending 2025-12-31 was $3.27K, a 43.70% decline year-over-year.
- BioNexus Gene Lab Corp. financing interest expense for the quarter ending 2025-09-30 was $6.48K, a 4.67% increase year-over-year.
- BioNexus Gene Lab Corp. financing interest expense for fiscal 2025 was $19.54K, a 7.59% decline from fiscal 2024.
- BioNexus Gene Lab Corp. financing interest expense for fiscal 2024 was $21.15K, a 51.81% increase from fiscal 2023.
- BioNexus Gene Lab Corp. financing interest expense for fiscal 2023 was $13.93K.
| Period end | Financing Interest Expense 3 month | Financing Interest Expense 6 month | Financing Interest Expense 9 month | Financing Interest Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.05K 10-Q · filed 2026-08-14 | $7.14K 10-Q · filed 2026-08-14 | $10.41K derived: sum of 3 quarters · filed 2026-08-14 | $16.89K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $3.08K 10-Q · filed 2026-05-15 | $6.36K derived: sum of 2 quarters · filed 2026-05-15 | $12.84K derived: sum of 3 quarters · filed 2026-05-15 | $17.72K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $3.27K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-14 | $9.75K derived: sum of 2 quarters · filed 2026-04-14 | $14.63K derived: sum of 3 quarters · filed 2026-08-14 | $19.54K 10-K · filed 2026-04-14 |
| 2025-09-30 | $6.48K 10-Q · filed 2025-11-14 | $11.36K derived: sum of 2 quarters · filed 2026-08-14 | $16.27K 10-Q · filed 2025-11-14 | $22.08K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $4.88K 10-Q · filed 2026-08-14 | $9.79K 10-Q · filed 2026-08-14 | $15.60K derived: sum of 3 quarters · filed 2026-08-14 | $21.79K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $4.91K 10-Q · filed 2026-05-15 | $10.72K derived: sum of 2 quarters · filed 2026-05-15 | $16.91K derived: sum of 3 quarters · filed 2026-05-15 | $21.39K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $5.81K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-14 | $12.01K derived: sum of 2 quarters · filed 2026-04-14 | $16.48K derived: sum of 3 quarters · filed 2026-04-14 | $21.15K 10-K · filed 2026-04-14 |
| 2024-09-30 | $6.19K 10-Q · filed 2025-11-14 | $10.67K derived: sum of 2 quarters · filed 2025-11-14 | $15.33K 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $4.48K 10-Q · filed 2025-08-18 | $9.14K 10-Q · filed 2025-08-18 | ||
| 2024-03-31 | $4.66K 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $13.93K 10-K · filed 2025-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |